Skip to main content
Medical information Clinical review pending

Genetic Testing

COG5 Gene Glycosylation Disorder Type 2I Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to identify mutations in the COG5 gene associated with Glycosylation Disorder Type 2I, a metabolic disorder. Helps in early diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample, Extracted DNA, or One drop of blood on an FTA card.
Results
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history review and genetic counseling session, including a pedigree chart of affected family members, are recommended before the test.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the COG5 Gene Glycosylation Disorder Type 2I Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of Glycosylation Disorder Type 2I.
  • ✓Patients presenting with symptoms suggestive of a metabolic disorder.
  • ✓Developmental delays or unexplained organ dysfunction.
  • ✓Genetic counseling for family planning.
  • ✓Confirmation of diagnosis in suspected cases.
02

In plain language

What this test helps you understand

This test identifies mutations in the COG5 gene, aiding in the diagnosis of Glycosylation Disorder Type 2I. It can help confirm a diagnosis in individuals with suggestive symptoms or a family history, guide treatment decisions, and inform genetic counseling for families.
The COG5 Gene Glycosylation Disorder Type 2I NGS Genetic DNA Test is an advanced diagnostic tool that uses Next-Generation Sequencing (NGS) technology. It looks for specific changes (mutations) in the COG5 gene. Mutations in this gene can lead to Glycosylation Disorder Type 2I, which affects how the body processes sugars and builds certain proteins, potentially causing metabolic disorders. Understanding your genetic makeup through this test is important for early diagnosis and managing potential health issues, especially if there is a family history of glycosylation disorders. This test provides valuable insights into potential health risks and can guide healthcare decisions. The test analyzes the COG5 gene to identify mutations that can disrupt the glycosylation process, essential for the proper function of many proteins. Results are typically available within 3 to 4 weeks. Your healthcare provider will help interpret the results and discuss any necessary next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history review and genetic counseling session, including a pedigree chart of affected family members, are recommended before the test.
SampleBlood sample, Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the COG5 gene for mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the COG5 gene. It may not detect mutations in other genes that can cause similar conditions. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Glycosylation Disorder Type 2I is a rare metabolic disorder caused by mutations in the COG5 gene. It affects the body's ability to properly process sugars and build certain proteins.
Individuals with symptoms suggestive of a metabolic disorder, developmental delays, or a family history of Glycosylation Disorder Type 2I should consider this test.
A sample can be collected as a blood draw, extracted DNA, or a single drop of blood on an FTA card.
Results are typically available within 3 to 4 weeks. Confirm with the laboratory before booking.
The test measures the presence of mutations in the COG5 gene using Next-Generation Sequencing (NGS) technology.
Yes, a genetic counseling session and clinical history review are recommended before the test to understand the implications and family history.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp